Current anti-obesity agents such as GLP-1 RA primarily reduce body weight by suppressing appetite through central mechanisms and secondarily improve glycemic control [11,35]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.